Phase 2 N=32 Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
Epidermolysis Bullosa
Primary: Percentage of Participants With Event-free Survival — 67; 80; 50; 29 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=212 An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
Primary Mitochondrial Myopathy
Primary: Change in Distance Walked During a 12 Minute Walk Test — 26.75; 30.89 meters
Phase 2 N=52 Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Malignant Glioma · Glioblastoma Multiforme · Anaplastic Astrocytoma
Primary: Number of Participants With Treatment Related Adverse Events — 21 Participants
Phase 2 N=73 Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
Essential Thrombocythemia
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 73 Participants
Phase 2 N=255 Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
Metastatic Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment — 5.6…
Phase 2 N=6 A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Solid Cancer
Primary: Number and Severity of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 6; 6; 3 participants
Phase 2 N=126 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Phase 1b: Number of Participants With Adverse Events as Per Severity — 0; 0; 2; 26 Participants
Phase 2 N=70 Nonopioid Analgesia After Rotator Cuff Repair
Rotator Cuff Tear
Primary: Pain Levels — 2.4; 3 units on a scale
Phase 2 N=27 Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis
Ulcerative Colitis · Inflammatory Bowel Diseases
Primary: Clinical Response — 5; 2; 1 Participants
Phase 2 N=101 A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
NASH
Primary: Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 6; 4; 7; 7 Participants
Phase 2 N=33 Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma
CNS Lymphoma · CNS Brain Cancer · Non-Hodgkin's Lymphoma
Primary: Number of Participants Evaluated for Toxicity — 33 Participants
Phase 2 N=6 A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Nonsene Mutation Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5 Participants
Phase 2 N=8 Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
Multiple Myeloma
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Phase 2 N=34 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Phase 2 N=28 Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Sars-CoV2 · Acute Respiratory Distress Syndrome · COVID-19
Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant